Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions

Current Vascular Pharmacology

Volumn 4, Issue 3, 2006, Pages 253-268

  Lonn, Eva ^a   Grewal, Jasmine ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Antiplatelet agents; Beta blockers; Cardiac rehabilitation; Cardiovascular disease; Cardiovascular prevention; Myocardial infarction; Statins; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NICOTINIC ACID; OMEGA 3 FATTY ACID; PERINDOPRIL; PLACEBO; PRAVASTATIN; PROSTAGLANDIN SYNTHASE; RAMIPRIL; RESIN; SIMVASTATIN; TELMISARTAN; THROMBOXANE A2; TICLOPIDINE; TRANDOLAPRIL; UNINDEXED DRUG; FIBRINOLYTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; BLEEDING; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; EVIDENCE BASED PRACTICE; EXERCISE; FATIGUE; HALLUCINATION; HEART BLOCK; HEART INFARCTION; HEART REHABILITATION; HEPATITIS; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; MEDICAL RESEARCH; META ANALYSIS; MONOTHERAPY; NIGHTMARE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SEXUAL DYSFUNCTION; STROKE; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS; ANIMAL; CARDIOLOGY; CHEMOPROPHYLAXIS; DYSLIPIDEMIA; PATIENT EDUCATION; PRACTICE GUIDELINE; RECURRENT DISEASE; RISK REDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ASPIRIN; ATHEROSCLEROSIS; CARDIOLOGY; CARDIOVASCULAR DISEASES; CHEMOPREVENTION; DYSLIPIDEMIAS; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; PATIENT EDUCATION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RISK REDUCTION BEHAVIOR;

EID: 33747847488     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106777698360     Document Type: Review

References (155)

1. Yusuf S, Ôunpuu S. Tackling the growing global burden of atherosclerotic cardiovascular diseases. Eur J Cardiovasc Prev Rehabil 2003; 10: 236-239.
2. Yusuf S, Reddy S, Ôunpuu S, Anand S. Global burden of cardiovascular diseases. Part I: general considerations, the epidemiological transition, risk factors, and impact of urbanization. Circulation 2001; 104: 2746-2753.
3. Yusuf S, Reddy S, Ôunpuu S, Anand S. Global burden of cardiovascular diseases. Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104: 2855-2864.
4. De Backer G, Ambrosione E, Borch-Johnson K, Brotons C, Cifkova R, Dallongeville J, et al. for the Third Joint Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003; 10(Suppl 1): S1-S78.
5. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 2004; available at www.acc.org/clinical/ guidelines/stemi/index.pdf.
6. Braunwald E, Antman E, Beasley J, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40: 1366-74.
7. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol 2004; 43: 900-921.
8. Smith S Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. ACC/AHA guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 001 update. Circulation 2001; 104: 1577-1579.
9. Snow V, Barry P, Fihn SD, Gibbons RJ, Owens DK, Williams SV, et al. American College of Physicians; American College of Cardiology Chronic Stable Angina Panel. Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004; 141: 562-567.
10. Cohen JD. ABCs of secondary prevention of CHD: easier said than done. Lancet 2001; 357: 972-973.
11. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N Engl Med 1976; 295:369-77.
12. Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 1976; 295:410-5.
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-421.
14. Fuster V, Morena PR, Fayad ZA, Corti R, Badimon JJ. Atherosclerosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005; 46:937-954.
15. Libby P. Inflammation and atherosclerosis. Nature 2002; 420: 868-874.
16. Libby P, Ridker PM. Inflammation and atherosclerosis. Circulation 2002: 105: 1135-1143.
17. Szmitko PE, Wang C-H, Weisel RD, Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003; 108: 1917-23.
18. Szmitko PE, Wang C-H, Weisel RD, Jeffries GA, Almeida JR, Anderson TJ, et al. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003: 28; 108:2041-8.
19. Griendling KK, Garret AF. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003; 108: 1912-1916.
20. Griendling KK, Garret FA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 2003; 108: 2034-2040.
21. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91: 7A-11A.
22. Behrendt D, Ganz P. Endothelial function: from vascular biology to clinical applications. Am J Cardiol 2002; 90 (Suppl): 40L-48L.
23. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105: 546-9.
24. Lerman A, Zeiher. AM. Endothelial Function: Cardiac Events. Circulation 2005; 111: 363 - 368.
25. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawis MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
26. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109(21 Suppl 1): II27-33.
27. Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med 2002; 162: 2405-10.
28. American Heart Association. Heart Disease & Stroke Statistics - 2005 Update. Dallas, Texas. American Heart Association © 2005.
29. Yusuf S, Hawken S, Ounpuu S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
30. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2002; 29; 324: 1570-1576.
31. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423.
32. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 28; 326: 1427.
33. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
34. Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med 1998; 3: 241-245.
35. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 13: 349-360.
36. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, et al. Aspirin, SU or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369-1375.
37. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581.
38. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
39. Patrono C, Bachman F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. for the Task Force on the Use of Antiplatelet Agents in Patients with Cardiovascular Disease of the European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. Eur Heart J 2004; 25: 166-181.
40. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Henneckens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9. Erratum in: N Engl J Med 1997; 337: 356.
41. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
42. Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321: 501-507.
43. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 2000; 31: 1779-84.
44. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment evaluation. N Engl J Med 2001; 345: 494-502.
45. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med 2005; 352: 1179-1189.
46. Bhatt DL, Topol EJ. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance Executive Committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004; 148: 263-8.
47. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003; 41(4 Suppl S): 62S-69S.
48. Weitz JI, Hirsch J, Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl): 265S-286S.
49. Campbell CL, Steinhubl SR. Variability in response to aspirin: do we understand the clinical relevance? J Thromb Haemost 2005; 3: 665-9.
50. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of International Society of Thrombosis and Hemostasis; Working Group on Aspirin Resistance: Position paper of the working group an aspirin resistance. J Thromb Hemost 2005; 3: 1309-1311.
51. The Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-blockers. Eur Heart J 2004; 25: 1341-1362.
52. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
53. The Beta-Blocker Pooling Project Research Group. The beta-blocker pooling project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988; 9: 8-16.
54. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-97.
55. Freemantle N, Cleland J, Young P, Mason J, Harisson J. Beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-1737.
56. Nuttall SL, Toescu V, Kendall MJ. Beta Blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction. BMJ 2000; 320: 581-587.
57. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left- ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.
58. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288: 351-357.
59. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll 2001; 37: 1950-1956.
60. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769-1776.
61. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-372.
62. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk factor Intervention Trial Research Group. Arch Int Med 1992; 152: 1490-1500.
63. Pederson TR, Olsson AG, Faegeman O, Kjekshus J, Wedel H, Berg K, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1452-1460.
64. Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, et al. Relationship between lipid levels and clinical outcomes in the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels. Circulation 2002; 105: 1162-1169.
65. Clarke R, Lewington S, Youngman L, Sherliker P, Peto R, Collins R. Underestimation of the importance of blood pressure and cholesterol for coronary heart disease mortality in old age. Eur Heart J 2002; 23: 286-293.
66. Rosengren A, Hagman M, Wedel H, Wilhelmsen L. Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris. A 16-year follow-up of the Primary Prevention Study in Goteborg, Sweden. Eur Heart J 1997; 381: 754-761.
67. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, et al. Ten year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-1707.
68. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening and myocardial infarction. The Framingham Study. Atherosclerosis 1988; 8: 207-211.
69. Assman G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19 (Suppl A): A2-A11.
70. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. High triglycerides and low HDL cholesterol and blood pressure and risk of ischemic heart disease. Hypertension 2000; 36: 226-232.
71. Ginsberg HN. Is hypertriglyceridemia a risk factor for atherosclerotic cardiovascular disease? A simple question with a complicated answer. Ann Intern Med 1997; 126: 912-914.
72. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-587.
73. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684-691.
74. Martinez-Gonzalez J, Raposo B, Rodriguez C. 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs. Aterioscler Thromb Vasc Biol 2001; 21: 122-128.
75. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933.
76. Albert MA, Danielson E, Rifai N, Ridker PM:PINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
77. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Pael S, et al. Simvastatin has anti-inflammatory and anti-atherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115-121.
78. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
79. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009
80. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. The Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
81. Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
82. Colhoun HM, Betteridge DJ, Darrington PN, Hitman GA, Neil HA, Livingstone SJ, et al.: CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
83. Cholesterol Treatment Trialists' (CTT) Collaborators. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of cholesterol-lowering treatment: prospective meta-analyses of individual data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
84. Campeau L, Knatterud GL, Domanski M, for The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153-162.
85. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 2004; 291: 1071-1080.
86. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
87. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 8: 1495-1504.
88. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. for the A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-1316.
89. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchaart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
90. Grundy SM, Cleeman JI, Bairey-Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-732.
91. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567-572.
92. Rubins HB, Robins SJ, Collins D, Fey CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High- Density Lipoprotein Cholesterol Intervention Trial Study Group. N Eng J Med 1999; 341:410-8.
93. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardioco (GISSI)-Prevenzione. Circulation 2002; 105: 1897-903.
94. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-2415.
95. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL cholesterol. N Engl J Med 2004; 350: 1505-1515.
96. Nissen S, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-2300.
97. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645.
98. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002; 105: 393-396.
99. Nickenig G, Harrison DG, The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation. Circulation 2002; 105: 530-536.
100. Dzau VJ. Thecardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens 2005; 23 (Suppl 1)S9-S17.
101. Dzau VJ, Berstien K, Celermajer D, Cohen J, Dahlof B, Deanfield J, et al. Pathophysiologic and Therapeutic Importance of Tissue ACE: A Consensus Report. Cardiovasc Drugs Ther 2002; 16: 149-160.
102. Brown NJ, Vaughan DE. Angiotensin-Converting Enzyme inhibitors. Circulation 1998; 97: 1411-1420.
103. Lonn E, Gerstein HC, Smieja M, Mann JFE, Yusuf S. Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. European Heart J 2003; 5(Suppl A): A43-A48.
104. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004; 25: 1454-70.
105. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
106. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
107. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
108. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-677.
109. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342: 821-828.
110. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354: 9-12.
111. Lonn E, Shaikholeslami R, Yi Q, Bosch J, Sullivan B, Tanser P, et al. Effect of ramipril on left ventricular mass and function in normotensive high risk patients with preserved left ventricular ejection fraction: a substudy of the HOPE trial. J Am Coll Cardiol 2004; 43: 2200-2206.
112. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 258-265.
113. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, et al. for the SECURE Investigators. Effects of ramipril and of vitamin E on atherosclerosis: results of the prospective randomized Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-925.
114. Heart Outcomes Prevention Evaluation Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
115. EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
116. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al.; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-2068.
117. The HOPE/ HOPE-TOO Investigators. Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes: Results of the HOPE Study Extension. Circulation 2005; 112: 1339-1346.
118. Pilote L, Abrahamovicz M, Rodrigues E, Eisenberg MJ, Rahme E. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004; 141: 102-112.
119. Wienbergen H, Schiele R, Gitt AK, Juenger C, Heer T, Meisenzahl C, et al.: MITRA PLUS Study Group. Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of un-selected patients with ST-elevation acute myocardial infarction. Am J Cardiol 2002; 90: 1045-1049.
120. The HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE study. Lancet 2000; 355: 253-259.
121. Daly CA, Fox KM, Remme ME, Ferrari R, Simoons ML. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 200l; 26: 1369-1378.
122. Yusuf S, Gerstein HC, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, et al. HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-1885.
123. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J: The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004; 47: 1519-27.
124. Dahlöf B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
125. Pfeffer M, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al.; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
126. Pfeffer M, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al.: Valsartan in Acute Myocardial Infarction Investigators; Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906. Erratum in: N Engl J Med 2004; 350: 203.
127. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Anderson S, Arner P, et al.: Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
128. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
129. Brenner EM, Cooper ME, de Zuew D, Keane WF, Mitch WE, Parving HH, et al.; RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
130. Teo KK, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, et al.: ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52-61.
131. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
132. Brown NJ. Eplerenone: cardiovascular protection. Circulation 2003; 107: 2512-2518.
133. Pitt B, Remme W, Zannad F, Neaton J, Martinez, F, Roniker B, et al.: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. Erratum in: N Engl J Med 2003; 348: 2271.
134. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum J. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
135. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S: The antioxidant vitamins (E,C and beta-carotene) and cardiovascular disease: a critical summary of epidemiological and clinical trial data. Ann Int Med 1995; 123: 860-872.
136. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003; 361: 2017-2023.
137. Lonn E, Bosch J, Arnold M, Sheridan P, Pogue J, Arnold JM, et al.; The HOPE and HOPE-TOO Study Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer. The HOPE study extension. JAMA 2005; 293: 1338-1347.
138. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
139. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006; 151: 282-287.
140. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 769-775.
141. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273: 199-208.
142. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002; 288: 2432-2440.
143. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin
144. US Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med 2005; 142: 855-860.
145. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
146. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
147. O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS Jr, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80: 234-244.
148. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995-1001.
149. Fletcher GF, Balady GJ, Vogel RA. Bethesda Conference Report. 33rd Bethesda Conference: Preventive Cardiology: How can we do better? J Am Coll Cardiol 2002; 40: 579-651.
150. Bradshaw P, Jamrozik K, Gilfillan I, Thompson PL. Preventing recurrent events long term after coronary artery bypass graft: suboptimal use of medications in a population study. Am Heart J 2004; 147: 1047-1053.
151. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004; 171: 1189-1192.
152. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med 2004; 164: 203-209.
153. Wald NJ, Law R. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326: 1419. Erratum in: BMJ 2003; 327: 586.
154. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2-3.
155. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Roers, E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 2004; 109: 745-749.